NORMAN, OKLA. – The University of Oklahoma has awarded nearly $200,000 in pilot seed funding to 20 artificial intelligence projects designed to spark innovation across health care, education, research and digital infrastructure. These faculty-led initiatives span a wide range of disciplines, showcasing OU’s commitment to empowering responsible and transformative uses of AI.
“These staff and faculty-led projects will move fast and create deliverables by the end of August,” said Yessenia Torres, senior managing director for the OU Data Institute for Societal Challenges, which is administering the initiative. “The researchers who are leading the projects will host office hours and workshops to invite anyone interested in their topics to learn more. The goal is to share their models so that others can replicate them."
The funded projects are:
Learn more about AI at OU, including research, use cases, news and more.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. For more information about the university, visit www.ou.edu.
Robin Zape-tah-hol-ah Starr Minthorn (Kiowa), professor and chair of the Department of Educational Leadership and Policy Studies in the University of Oklahoma Jeannine Rainbolt College of Education, has been elected president of the Association for the Study of Higher Education (ASHE) — becoming the first Indigenous person to hold this role in the organization’s history.
A new study from the University of Oklahoma suggests that small genetic differences in two proteins – previously known for their role in premature infants’ lungs – may also influence how their eyes develop, potentially affecting the risk of retinopathy of prematurity (ROP).
University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs, like Ozempic and Zepbound, on cancer risk.